Pulnovo Medical Showcases Pulmonary Vascular Technology at Major Heart Failure Congress

A LinkedIn post from Pulnovo Medical highlights the company’s planned participation at Heart Failure 2026, an academic congress organized by the Heart Failure Association of the ESC in Barcelona. The post suggests the company aims to showcase its proprietary pulmonary vascular intervention technology to a global clinical audience.

According to the post, Pulnovo references recent milestones including EU‑MDR CE certification and an FDA IDE clinical trial that is currently enrolling in both the U.S. and EU. These points indicate ongoing efforts to secure broader regulatory validation and clinical evidence, which may be important precursors to commercial expansion.

The post notes that Pulnovo will feature academic content on device therapy for pulmonary hypertension due to left heart disease and a live case walkthrough in pulmonary arterial hypertension. This scientific emphasis may reinforce the company’s positioning as a specialized medtech player in pulmonary vascular interventions and could help build clinical KOL support.

For investors, the referenced CE mark under EU‑MDR and progress of the FDA IDE trial, if successfully advanced, may expand future revenue opportunities in major markets. Visibility at a leading heart failure congress may also aid in physician adoption and partnership discussions, although commercial impact will depend on trial outcomes, reimbursement, and competitive dynamics in pulmonary hypertension device therapies.